Tarsus Pharmaceuticals (TARS) Expected to Announce Quarterly Earnings on Wednesday

Tarsus Pharmaceuticals (NASDAQ:TARS) is anticipated to announce its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.3767) per share and revenue of $151.15 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. On average, analysts expect Tarsus Pharmaceuticals to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded up $0.74 during midday trading on Monday, hitting $64.36. 7,040 shares of the company were exchanged, compared to its average volume of 561,162. The firm has a market capitalization of $2.77 billion, a P/E ratio of -39.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The firm’s 50 day moving average price is $69.07 and its two-hundred day moving average price is $72.07. Tarsus Pharmaceuticals has a 52 week low of $38.51 and a 52 week high of $85.25.

Analyst Ratings Changes

Several analysts recently commented on TARS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Friday, April 24th. They issued an “outperform” rating and a $98.00 price objective for the company. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $90.67.

Insider Activity

In other news, General Counsel Bryan Wahl sold 4,231 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $283,477.00. Following the completion of the transaction, the general counsel directly owned 63,959 shares in the company, valued at approximately $4,285,253. The trade was a 6.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dianne C. Whitfield sold 4,174 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $279,658.00. Following the completion of the transaction, the insider owned 35,028 shares of the company’s stock, valued at $2,346,876. The trade was a 10.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 79,391 shares of company stock valued at $5,432,035 over the last quarter. 8.97% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board grew its holdings in shares of Tarsus Pharmaceuticals by 1.1% during the 4th quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock valued at $2,613,000 after purchasing an additional 332 shares during the last quarter. Federated Hermes Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 0.6% during the 2nd quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after purchasing an additional 339 shares during the last quarter. Creative Planning grew its holdings in shares of Tarsus Pharmaceuticals by 3.3% during the 3rd quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after purchasing an additional 393 shares during the last quarter. Truvestments Capital LLC grew its holdings in shares of Tarsus Pharmaceuticals by 106.1% during the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after purchasing an additional 468 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 3.6% during the 3rd quarter. Franklin Resources Inc. now owns 22,183 shares of the company’s stock valued at $1,318,000 after purchasing an additional 781 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.